Bajaj Healthcare Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8s1skr4xxzk5lremly4dsmk4.pdf

Key Takeaways


Revenue Drivers: Formulations Rebound and Export Momentum

Anil Jain: "As you know, always API is always on pressure. Price pressure is there, even the demand pressure is there. Over the period of time, there not be much improvement in the API pricing. It will be a straight line."

Cenobamate: The Near-Term Differentiator

Anil Jain: "We do a primary sale. We are into B2B with eight partners. So What is their sale, still we don't have, because we have launched this product in September itself. But the one good thing is that we have got a repeated orders from them, so this clearly shows that their secondary sales are moving very well."

Margins: Mix Shift Offset the Gross Margin Dip

Rohan Parekh: "We are pretty confident of maintaining this gross margin and EBITDA margins. We do have a vast product mix where we can calibrate it much better in the coming quarters so that we are able to maintain it."

Peptides and Oncology: The FY28 Growth Engines

Anil Jain: "But the main key remains is the API. How many manufacturers are there in India who will be manufacturing the API with this capacity of 250 kg. So we believe that we have a very good position with the peptides."

Strategic Build-Out: Facilities, Talent, and the Revenue Mix Ambition


Guidance & Commitments

CommitmentSpecificsTimeline
FY27 growth and marginRevenue and profit growth of 10–15%, EBITDA margin of 18–20%FY27
FY29 revenue and margin targetRevenue of ₹900–1,000 crores, EBITDA margin of 18–21%FY29
Peptide plant completionCommercial manufacturing facility with 250 kg/year capacity31 March 2027
Peptide first-year revenue₹70–100 crores from peptide facilityFY28–29
Peptide cumulative revenue~₹300 crores cumulative in the year after FY28–29FY29–30 (implied)
Oncology plant startAPI and formulation plant commencing operationsQ2 FY28
Oncology revenue ramp~₹200 crores revenue from oncology facilityWithin 2–3 years of start
Genrx revenue contribution₹200–250 crores from Genrx facilityWithin 2–3 years of start
Nashik formulation plantOperational for solid oral dosage and other formatsQ1 FY28
Formulation revenue mix targetFormulations to reach 45–50% of total revenue3–4 years
Oncology backward integration60–70% of oncology products backward integrated, adding 10–15% margin2–3 years
FY27 capexTotal capex of ₹65–80 croresFY27
Annual capex thereafter₹50–60 crores annually to support ₹1,000 crore targetFY28 onward
FY27 operating cash flowMore than ₹30 crores, with improving EBITDA-to-OCF conversionFY27

Key Metrics

MetricQ2 FY27
Revenue from operations₹175.9 cr, up 18.9% YoY and 6.2% QoQ
H1 FY27 revenue from operations₹341.5 cr, up 15.1% YoY from ₹296.8 cr in H1 FY26
Gross margin48.3%, in line with Q1 FY27; gross profit ₹85.4 cr, up 12.4% YoY
EBITDA₹32.1 cr, up 12.2% YoY and 8.6% QoQ
EBITDA margin18.2%, improved sequentially from 17.8%
H1 FY27 EBITDA margin18.1%
Profit after tax₹14.1 cr, up 26.9% YoY; PAT margin 8% vs 7.5% in Q2 FY26
H1 FY27 PAT₹27.8 cr, up 21.1% YoY; PAT margin 8.1% vs 7.7% in H1 FY26
Formulations revenue₹41.7 cr, up 82% YoY and 78.8% QoQ
API export revenue₹62.6 cr, up 28.5% YoY and 25.1% QoQ
Domestic API revenue₹71.6 cr, vs ₹76.3 cr in Q2 FY26 and ₹92 cr in Q1 FY27
API export plus formulations revenueCrossed ₹100 cr, now close to 60% of total revenue
Net worth~₹557 cr as of 30 Sep 2026, up from ₹533 cr in Mar 2026
Debt-to-equity~0.5x
FY27 capex guidance₹65 cr to ₹80 cr
FY29 revenue target₹900 cr to ₹1,000 cr, with EBITDA margin of 18% to 21%
R&D spending~2.5% to 3% of revenue
CEP filings12 filed, 8 approved, 4 under review
South Korea KDMF registrations17 total, 2 added in Q2
Peptide plant capacity250 kg per annum, completion targeted by 31 Mar 2027
Peptide APIs developed at pilot scale6
Receivable turnover135 days, improved from 145 days
H1 FY27 operating cash flow~₹15 cr
Full FY27 operating cash flow expectationMore than ₹30 cr